These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 7507404

  • 21. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM.
    J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
    [Abstract] [Full Text] [Related]

  • 22. Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ.
    Eur J Cancer; 1997 Oct; 33(11):1896-9. PubMed ID: 9470854
    [Abstract] [Full Text] [Related]

  • 23. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Kemeny N, Conti JA, Seiter K, Niedzwiecki D, Botet J, Martin D, Costa P, Wiseberg J, McCulloch W.
    J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
    [Abstract] [Full Text] [Related]

  • 24. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
    Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H.
    Eur J Cancer; 1999 Mar; 35(3):380-5. PubMed ID: 10448286
    [Abstract] [Full Text] [Related]

  • 25. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Kelsen D, Martin DS, Colofiore J, Sawyer R, Coit D.
    Cancer; 1992 Oct 01; 70(7):1988-92. PubMed ID: 1381991
    [Abstract] [Full Text] [Related]

  • 26. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
    Buroker TR, Moertel CG, Fleming TR, Everson LK, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Klaassen DJ, Laurie JA.
    J Clin Oncol; 1985 Dec 01; 3(12):1624-31. PubMed ID: 2933492
    [Abstract] [Full Text] [Related]

  • 27. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin.
    Rustum YM, Cao S, Zhang Z.
    Cancer J Sci Am; 1998 Dec 01; 4(1):12-8. PubMed ID: 9467039
    [Abstract] [Full Text] [Related]

  • 28. [Chronotherapy with high dose carboplatin, 5-fluorouracil and leucovorin in advanced colorectal carcinoma].
    Popov I, Jelić S, Radosavljević D, Nikolić-Tomasević A.
    Srp Arh Celok Lek; 1998 Dec 01; 126(9-10):355-61. PubMed ID: 9863407
    [Abstract] [Full Text] [Related]

  • 29. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cao S, Rustum YM, Spector T.
    Cancer Res; 1994 Mar 15; 54(6):1507-10. PubMed ID: 8137256
    [Abstract] [Full Text] [Related]

  • 30. Biochemical modulation of 5-fluorouracil by PALA.
    O'Dwyer PJ.
    Cancer Invest; 1990 Mar 15; 8(2):261-2. PubMed ID: 2400945
    [No Abstract] [Full Text] [Related]

  • 31. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Stridhar K, Reddy R, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Livingstone A.
    Int J Radiat Oncol Biol Phys; 1992 Mar 15; 22(3):511-4. PubMed ID: 1735689
    [Abstract] [Full Text] [Related]

  • 32. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Ragnhammar P, Blomgren H.
    Med Oncol; 1995 Sep 15; 12(3):187-201. PubMed ID: 8852401
    [No Abstract] [Full Text] [Related]

  • 33. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    O'Dwyer PJ, Paul AR, Walczak J, Weiner LM, Litwin S, Comis RL.
    J Clin Oncol; 1990 Sep 15; 8(9):1497-503. PubMed ID: 2391557
    [Abstract] [Full Text] [Related]

  • 34. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Makower D, Wadler S.
    Semin Oncol; 1999 Dec 15; 26(6):663-71. PubMed ID: 10606259
    [Abstract] [Full Text] [Related]

  • 35. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E, Beuzeboc P, Deffontaines D, Diéras V, Dorval T, Jouve M, Palangie T, Scholl S, Pouillart P.
    J Infus Chemother; 1996 Dec 15; 6(3):149-51. PubMed ID: 9229328
    [Abstract] [Full Text] [Related]

  • 36. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
    Abad A, Garcia P, Gravalos C, Tusquets I, Font A, Perez G, Cortés-Funes H, Fabregat X, Barnadas A, Rosell R.
    Cancer; 1995 Mar 15; 75(6):1238-44. PubMed ID: 7882275
    [Abstract] [Full Text] [Related]

  • 37. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Ardalan B, Ucar A, Reddy R, Livingstone AS, Markoe A, Schwade J, Richman SP, Donofrio K.
    Cancer; 1994 Oct 01; 74(7):1869-73. PubMed ID: 8082092
    [Abstract] [Full Text] [Related]

  • 38. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ, European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    J Clin Oncol; 2003 Oct 15; 21(20):3721-8. PubMed ID: 12963704
    [Abstract] [Full Text] [Related]

  • 39. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassineti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, Grossi F, Labianca R.
    Br J Cancer; 2001 Apr 20; 84(8):1023-8. PubMed ID: 11308248
    [Abstract] [Full Text] [Related]

  • 40. Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
    Scheithauer W, Depisch D, Kornek G, Pidlich J, Rosen H, Karall M, Prochaska M, Ernst A, Sebesta C, Eckhardt S.
    Cancer; 1994 Mar 15; 73(6):1562-8. PubMed ID: 8156482
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.